Cite
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.
MLA
VanDevanter, D. R., et al. “Willingness of People with Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor (ETI) to Participate in Randomized Modulator and Inhaled Antimicrobial Clinical Trials.” Journal of Cystic Fibrosis, vol. 22, no. 4, July 2023, pp. 652–55. EBSCOhost, https://doi.org/10.1016/j.jcf.2023.04.007.
APA
VanDevanter, D. R., Zemanick, E. T., Konstan, M. W., Ren, C. L., Odem-Davis, K., Emerman, I., Young, J., & Mayer-Hamblett, N. (2023). Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials. Journal of Cystic Fibrosis, 22(4), 652–655. https://doi.org/10.1016/j.jcf.2023.04.007
Chicago
VanDevanter, D.R., E.T. Zemanick, M.W. Konstan, C.L. Ren, K. Odem-Davis, I. Emerman, J. Young, and N. Mayer-Hamblett. 2023. “Willingness of People with Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor (ETI) to Participate in Randomized Modulator and Inhaled Antimicrobial Clinical Trials.” Journal of Cystic Fibrosis 22 (4): 652–55. doi:10.1016/j.jcf.2023.04.007.